Cybin Inc.

CYBN

CA23256X1006

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
0.3561 ^USD	+2.06%		+1.74%	-13.15%

06/05	Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	CI
17/04	Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	MT

Cybin Inc. Announces that George Tziras Joins the Board of Directors and Will Serve as Chief Business Officer

October 23, 2023 at 05:03 pm IST

Cybin Inc. announced that George Tziras, the former Chief Executive Officer of Small Pharma, joined the board of directors and will serve as Cybin?s Chief Business Officer.

Latest news about Cybin Inc.

Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	06/05	CI
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	17/04	MT
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	16/04	MT
Cybin Inc. announced that it has received $150 million in funding from a group of investors	19/03	CI
Sector Update: Health Care Stocks Softer Friday Afternoon	15/03	MT
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	15/03	MT
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	15/03	CI
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial	14/03	MT
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	14/03	CI
Sector Update: Health Care Stocks Ease Wednesday Afternoon	13/03	MT
Cybin Says Depression Drug Granted Breakthrough Designation by FDA; Raises $150 Million in Private Placement; Shares Jump	13/03	MT
Transcript : Cybin Inc. - Special Call	13/03
Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder	13/03	CI
Cybin Inc. announced that it expects to receive $150 million in funding	13/03	CI
Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
Cybin Gets FDA Clearance for Generalized Anxiety Disorder Study	23/01	MT
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder	23/01	CI
Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028	08/01	CI
Cybin Inc. Announces Recent Positive Phase 2 CYB003 Topline Results in MDD and Outlines Key Upcoming Milestones Across its Clinical Development Programs	04/01	CI
Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting	06/12	CI
Transcript : Cybin Inc. - Special Call	30/11
Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses	30/11	CI
HC Wainwright Adjusts Cybin Price Target to $5 From $10, Maintains Buy Rating	17/11	MT
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	14/11	CI
Transcript : Cybin Inc. - Special Call	01/11

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Sector

Biotechnology & Medical Research

Calendar

19/06/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4865 CAD

Average target price

6.089 CAD

Spread / Average Target

+1,151.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYBIN INC.	-13.15%	271M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs

Cybin Inc.

Equities

CYBN

CA23256X1006

Biotechnology & Medical Research

Cybin Inc. Announces that George Tziras Joins the Board of Directors and Will Serve as Chief Business Officer

Latest news about Cybin Inc.

Chart Cybin Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs